Supplementary Table 6. Subgroup analyses according to weight change[a] for the effects of the four SHS exposure groups on new-onset hypertension in the overall population

	Person-years	No. of events	Incidence rate, 10,000 person-years	Hazard ratio (95% confidence interval) Multivariable model
Weight reduction > 1 kg				
No SHS exposure[d]	36,399	324	89.0	1
New SHS exposure[d]	2,244	23	102.5	1.30 (0.80–2.10)
Former SHS exposure[d]	8,206	70	85.3	0.67 (0.49–0.91)
Sustained SHS exposure[d]	3,887	46	118.4	1.16 (0.81–1.66)
Weight change –1 to 1 kg				
No SHS exposure[d]	45,946	302	65.7	1
New SHS exposure[d]	2,534	23	90.8	1.76 (1.13–2.73)[c]
Former SHS exposure[d]	10,151	89	87.7	1.08 (0.83–1.41)
Sustained SHS exposure[d]	4,175	50	119.8	1.46 (1.03–2.06)[b]
Weight gain > 1 kg				
No SHS exposure[d]	90,805	723	79.6	1
New SHS exposure[d]	5,515	60	108.8	1.17 (0.88–1.56)
Former SHS exposure[d]	22,386	206	92.0	0.87 (0.73–1.03)
Sustained SHS exposure[d]	8,557	91	106.4	1.04 (0.81–1.33)
Interaction p value by weight change				0.231

Multivariable model was adjusted for age, sex, body mass index, waist circumference, vigorous exercise (≥ 5 times/week), alcohol consumption, presence of diabetes, creatinine, uric acid, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, and high-sensitivity C-reactive protein.

SHS, secondhand smoke.

[a]Weight change was assessed by subtracting weight at baseline from that at follow-up, and was categorized as weight reduction (> 1 kg), no change, weight gain (> 1 kg) for subgroup analysis.

[b]$p < 0.05$.

[c]$p < 0.01$.

[d]The reference group was no SHS exposure group. No SHS exposure group was defined as individuals without SHS exposure both at baseline and at follow-up; New SHS exposure group as those without SHS exposure at baseline and with SHS exposure at follow-up; Former SHS exposure group as those with SHS exposure at baseline and without SHS exposure at follow-up; Sustained SHS exposure group as those with SHS exposure both at baseline and at follow-up.